Τίτλος:
Translocation t(12;13)(p13;q14) in a patient with imatinib-sensitive MDS/MPD associated with resistance to treatment: Review of the literature
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The category of myelodysplastic syndromes/myeloproliferative diseases (MDS/MPD) is a relatively new group of malignant hematologic diseases developed by the World Health Organization. These hematologic disorders lack the BCR/ABL fusion gene, although they can be associated with chromosomal translocations that involve genes encoding other protein kinases. Imatinib mesylate was recognized as a potent inhibitor of some of those kinases. We present a patient with a previously treated acute myeloid leukemia, who, after a 9-year-long remission, developed an MDS/MPD with normal karyotype, which initially responded to imatinib mesylate. Translocation t(12;13)(p12;q14) was detected after loss of response to imatinib treatment. Translocation t(12;13) is rare. It has been described in several hematologic malignancies including chronic myelomonocytic leukemia but not in MDS/MPD, previously described as Philadelphia-negative chronic myelogenous leukemia. Moreover, the correlation of this molecular abnormality with loss of efficacy of imatinib is unique in the literature. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Συγγραφείς:
Diamantopoulos, P.T.
Athanasiadou, A.
Papakostas, E.
Gratsias, N.
Georgiou, G.
Mantzourani, M.
Andreopoulos, G.
Panagiotidis, P.
Aessopos, A.
Meletis, J.
Viniou, N.
Περιοδικό:
Anti-Cancer Drug Design
Λέξεις-κλειδιά:
CD33 antigen; CD34 antigen; CD45 antigen; cyclophosphamide; cytarabine; danazol; etoposide; Flt3 ligand; hydroxyurea; imatinib; methylprednisolone; microsomal aminopeptidase; mitoxantrone; platelet derived growth factor alpha receptor; platelet derived growth factor beta receptor; retinoblastoma protein; transcription factor ETV6; vincristine, acute granulocytic leukemia; adult; anemia; blood analysis; blood cell count; bone marrow biopsy; bone marrow examination; cancer regression; case report; cytogenetics; drug treatment failure; drug withdrawal; erythrocyte transfusion; fatigue; female; fluorescence in situ hybridization; gingiva bleeding; granulocyte; hematocrit; hemolytic anemia; human; human cell; human tissue; karyotype; karyotype 46,XX; leukocyte; leukopenia; malaise; mixed myelodysplastic myeloproliferative disease; monotherapy; physical examination; polymerase chain reaction; priority journal; review; thrombocytopenia; treatment response; upper gastrointestinal bleeding, Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Translocation, Genetic
DOI:
10.1097/CAD.0b013e3283486ca4
